Home ›
Entities
› academia
› Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective
Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective
Research article (Annals of Oncology, 2019) · cited 61× · AI/ML
Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective
Summary
Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective is a scholarly article[1].
Key Facts
Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective. Retrieved May 24, 2026, from https://4ort.xyz/entity/model-informed-drug-development-approach-supporting-approval-of-the-4-week-q4w-dosing-schedule-for-nivolumab-opdivo-acro
MLA“Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/model-informed-drug-development-approach-supporting-approval-of-the-4-week-q4w-dosing-schedule-for-nivolumab-opdivo-acro.
BibTeX@misc{4ortxyz_model-informed-drug-development-approach-supporting-approval-of-the-4-week-q4w-dosing-schedule-for-nivolumab-opdivo-acro_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective}}, year = {2026}, url = {https://4ort.xyz/entity/model-informed-drug-development-approach-supporting-approval-of-the-4-week-q4w-dosing-schedule-for-nivolumab-opdivo-acro}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective — https://4ort.xyz/entity/model-informed-drug-development-approach-supporting-approval-of-the-4-week-q4w-dosing-schedule-for-nivolumab-opdivo-acro (retrieved 2026-05-24)
